Israel's Protalix BioTherapeutics Q3 revenue rises, driven by higher sales to Chiesi

Overview

• Israel biopharma firm's Q3 revenue and net income rose yr/yr

• Company expects to meet or exceed 2026 revenue guidance

• Q3 results driven by higher sales to Chiesi, partially offset by lower sales to Fiocruz

Outlook

• Protalix expects 2026 total revenue of $78 mln to $83 mln

• Company forecasts 2026 Elfabrio sales, excluding milestones, of $33 mln to $35 mln

• Protalix anticipates 2026 Elelyso sales of $20 mln to $23 mln

Result Drivers

• HIGHER SALES TO CHIESI - Co said Q3 revenue growth was primarily driven by increased sales to Chiesi

• LOWER SALES TO FIOCruz - Q3 sales to Fiocruz (Brazil) declined, which partially offset revenue growth, per co

• LOWER LICENSE AND R&D REVENUE - Q3 revenue from license and R&D services fell due to fewer services provided to Chiesi

Company press release:

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 21 three months ago

Reuters Recommended Reads

• Nov 9 - Israel's Kamada Q3 revenue up 11%, raises forecast

• Nov 9 - Israel's Compugen Q3 revenue doubles on Gilead payments; loss narrows

• Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)